Tetrahydroisoquinoline-7-carboxamide based DDR1 inhibitor 7ae developed to treat acute lung injury (ALI) bind tightly to DDR1, reducing its kinase activity (106). Here, DDR1 is linked to acute respiratory distress syndrome.